We are live on ! Find out more
PLRX icon

Pliant Therapeutics
PLRX

77 hedge funds and large institutions have $512M invested in Pliant Therapeutics in 2021 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 30 increasing their positions, 18 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 18

0.98% less ownership

Funds ownership: 85.51% → 84.53% (-0.98%)

5% less funds holding

Funds holding: 81 → 77 (-4)

25% less funds holding in top 10

Funds holding in top 10: 4 → 3 (-1)

36% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 11

43% less capital invested

Capital invested by funds: $893M → $512M (-$381M)

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $812K

Holders
77
Holders Change
-4
Holders Change %
-4.94%
% of All Funds
1.35%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.05%
New
7
Increased
30
Reduced
18
Closed
11
Calls
–
Puts
$812K
Net Calls
-$812K
Net Calls Change
-$623K

Top Buyers

1
Vanguard Group
Vanguard Group
Pennsylvania
+$3.12M
2
Citadel Advisors
Citadel Advisors
Florida
+$2.76M
3
Morgan Stanley
Morgan Stanley
New York
+$2.49M
4
CA
CHI Advisors
New York
+$2.48M
5
WP
Woodline Partners
California
+$2.3M

Top Sellers

1
FCM
Farallon Capital Management
California
-$14.3M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$6.13M
3
EAM
Eventide Asset Management
Massachusetts
-$6.13M
4
RG
Redmile Group
California
-$1.55M
5
SFM
Sphera Funds Management
Israel
-$1.49M
Name Holding Trade Value Shares
Change 		Change in
Stake
TGI
1
TRV GP III
Massachusetts
$98.6M – – –
Fidelity Investments
2
Fidelity Investments
Massachusetts
$91M +$138K +6,522 +0.1%
RG
3
Redmile Group
California
$52M -$1.55M -72,900 -2%
CA
4
CHI Advisors
New York
$41.9M +$2.48M +116,836 +5%
EAM
5
Eventide Asset Management
Massachusetts
$36.9M -$6.13M -288,654 -12%
TGI
6
TRV GP IV
Massachusetts
$36M – – –
BlackRock
7
BlackRock
New York
$26.2M -$122K -5,730 -0.4%
Vanguard Group
8
Vanguard Group
Pennsylvania
$23.9M +$3.12M +146,943 +12%
Citadel Advisors
9
Citadel Advisors
Florida
$22.4M +$2.76M +129,961 +11%
HMC
10
Harvard Management Company
Massachusetts
$9.49M – – –
Bessemer Group
11
Bessemer Group
New Jersey
$9.07M – – –
CAM
12
Cormorant Asset Management
Massachusetts
$8.14M – – –
State Street
13
State Street
Massachusetts
$7.06M +$700K +32,995 +9%
Franklin Resources
14
Franklin Resources
California
$6.69M – – –
Geode Capital Management
15
Geode Capital Management
Massachusetts
$5.41M +$819K +38,598 +14%
Lord, Abbett & Co
16
Lord, Abbett & Co
New Jersey
$4.97M -$83.5K -3,936 -1%
Northern Trust
17
Northern Trust
Illinois
$3.79M +$185K +8,698 +4%
WP
18
Woodline Partners
California
$3.04M +$2.3M +108,330 +151%
FIM
19
Fernwood Investment Management
Massachusetts
$2.81M +$325K +15,336 +10%
Charles Schwab
20
Charles Schwab
California
$2.67M +$1.34M +63,282 +67%
Morgan Stanley
21
Morgan Stanley
New York
$2.55M +$2.49M +117,550 +349%
BDFN
22
Bond & Devick Financial Network
Minnesota
$2.03M – – –
N
23
Nuveen
North Carolina
$1.57M -$357K -16,811 -15%
IC
24
Ikarian Capital
Texas
$1.46M -$467K -21,988 -20%
D.E. Shaw & Co
25
D.E. Shaw & Co
New York
$1.28M -$291K -13,727 -15%
1
2 3 4

PLRX Hedge Fund Activity: Q3 2021 in Review

77 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Pliant Therapeutics (PLRX) for Q3 2021, worth a combined $512M — down 43% from $893M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of PLRX and 7 opened new positions — a net loss of 4 holders — while 18 trimmed existing stakes and 30 added.

The largest buyer was Vanguard Group, adding an estimated $3.12M. The largest seller was Farallon Capital Management, exiting entirely with an estimated $14.3M sold.

  • 77 institutional investors held Pliant Therapeutics (PLRX) as of Q3 2021, down from 81 in Q2 2021.
  • Funds reported $512M of Pliant Therapeutics stock for Q3 2021, down 43% quarter-over-quarter.
  • 7 funds opened new Pliant Therapeutics positions in Q3 2021 and 11 closed out, a net change of -4 holders.
  • The largest Pliant Therapeutics buyer in Q3 2021 was Vanguard Group, an estimated $3.12M added.
  • The largest Pliant Therapeutics seller in Q3 2021 was Farallon Capital Management, an estimated $14.3M sold.

Based on aggregated 13F filings for Q3 2021.